-
NMPA Notice on Matters Concerning the Registration of Drug-device Combination Products
2021-07-27
In accordance with relevant provisions for registration management of drugs and medical devices, matters concerning the registration of drug-device combination products are hereby announced on July 23 as follows.
-
NMPA Announcement on the Revision of the Package Insert of the Vitamin B6 Injection
2021-07-27
In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, NMPA decided to modify the items of [Adverse reactions] and [Contraindications] in the package inserts of Vitamin B6 injection.
-
NMPA Announcement on the Revision of the Package Insert of the Propranolol Tablets
2021-07-20
The NMPA decided to modify the items of [Precautions] in the package inserts of propranolol tablets. On July 15, relevant issues are hereby announced as follows.
-
NMPA Announcement on Issuing 6 Guidance including the Guidance for Nomenclature of the Generic Names of Medical Rehabilitation Devices
2021-07-15
The NMPA has organized to formulate the 6 Guidance including the Guidance for Nomenclature of the Generic Names of Medical Rehabilitation Devices, which are issued on July 12.
-
NMPA Announcement on Guidance for the Classification Defining of AI-Based Medical Software Products
2021-07-08
The NMPA has organized to formulate the Principles for the Classification Defining of AI-Based Medical Software Products, which was issued on July 1.
-
NMPA Announcement on the Revision of the Package Insert of Metoclopramide
2021-07-05
In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of [Adverse reactions], [Contraindications] and [Precautions] in the package inserts of Metoclopramide.
